The preliminary data from the pivotal cohort of the ongoing Phase 2 LEGEND trial showed a 62% complete response rate at six months among 37 patients. Following these results, Raymond James upgraded ...
The following slide deck was published by enGene Holdings Inc. in conjunction with this event.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback